Skip to main content
Caplight Logo









DiogenX

DiogenX

Private
MarseilleHealthcare & Life Scienceshttps://diogenx.com/

Last Round

Series A

Extension

Oct 31, 2023

Total Funding Raised

$45.05M

Company Overview

DiogenX is a biotechnology company that develops innovative biologics and regenerative therapies for the treatment of type 1 diabetes.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

regenerative medicinetype 1 diabetesbeta cell regenerationrecombinant proteinbiotechWnt signalingdrug discoverydisease-modifying therapybeta cell therapypreclinical biotechinsulin independencebiopharma partnershiptherapeutic candidatediabetes cure research

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

DiogenX Comparables

Compare DiogenX with similar companies based on industry and business-model similarity.

DiogenX comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Betavive Ltd.
85%
Wink Biotherapeutics
81%
Caspian Therapeutics, Inc.
81%

DiogenX Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionOct 31, 2023
GrantOct 1, 2023
Series AMay 10, 2023
SeedJun 16, 2020

DiogenX Investors

Notable investors and investment history

DiogenX investors
InvestorRounds
European Innovation Council FundGrant
Roche Venture FundSeries A
Boehringer IngelheimSeed, Series A
Roche Venture FundSeries A, Series A Extension
JDRFSeries A, Seed, Series A Extension
Boehringer Ingelheim Venture FundSeed, Series A, Series A Extension
Omnes CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 1, 2023

    $2.65M grant from the European Innovation Council Fund

DiogenX Filings

Explore SEC and related filing metadata, where available.

DiogenX filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about DiogenX's valuation, stock price, and market status.

Is DiogenX a public or private company?

DiogenX is a private company.

What is the current stock price of DiogenX?

DiogenX is a private company with no public stock price. No recent secondary market data is available.

How much is DiogenX worth (valuation)?

Valuation information for DiogenX is not publicly available.

Can I buy DiogenX stock?

DiogenX shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was DiogenX's last funding round?

DiogenX's most recent funding round was Series A Extension on October 31, 2023.

Who are the main investors in DiogenX?

Key investors in DiogenX include Boehringer Ingelheim, Roche Venture Fund, Boehringer Ingelheim Venture Fund, AdBio partners.

Will DiogenX IPO soon?

No public IPO plans have been announced for DiogenX.

How can I track DiogenX secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor DiogenX's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersMarseille
Employee Range19
Year Founded2020
Last FundingOct 31, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?